15/06/2026
Does Type 1 diabetes always mean lifelong insulin?
This is one of the first questions almost everyone asks after receiving a diagnosis. Insulin therapy remains the foundation of Type 1 diabetes treatment. However, additional approaches are now being explored with the goal of preserving the body's own insulin production and supporting pancreatic function.
What happens in Type 1 diabetes
In Type 1 diabetes, the immune system mistakenly attacks the beta cells of the pancreas that produce insulin. This process develops gradually, which means that at the time of diagnosis some beta cells are often still alive and functioning.
The "honeymoon phase" of diabetes
During the first months after diagnosis, many patients notice that their insulin requirements temporarily decrease and blood sugar becomes easier to control. Endocrinologists refer to this period as the "honeymoon phase."
During this time, the pancreas may still retain part of its insulin-producing capacity.
Why timing matters
The first 6 to 12 months after diagnosis are generally considered the most favorable period to consider MSC therapy. During this stage, residual insulin secretion is often still present and some beta-cell function may remain intact.
The earlier intervention is considered, the greater the opportunity to preserve remaining pancreatic function and endogenous insulin production.
🌿 How cell therapy works
MSC therapy (mesenchymal stromal cells) is intended to address several goals:
✅ Reduce autoimmune inflammation and immune-mediated damage to beta cells.
✅ Support and preserve the remaining insulin-producing cells.
✅ Create conditions that may help maintain pancreatic function.
This is not a replacement for insulin and not a promise of a complete cure. The goal is to preserve as much endogenous insulin production as possible and potentially influence the long-term course of the disease.
What is considered a successful outcome?
Many patients hope to become completely independent of insulin. However, a successful outcome may also include a significant reduction in insulin requirements, preservation of residual insulin secretion, and improved long-term disease control.
Even a small amount of endogenous insulin production may contribute to better metabolic control and a lower risk of diabetes-related complications.
When therapy may be relevant
The greatest potential benefit is generally expected during the early stages of the disease. However, patients with a longer history of Type 1 diabetes may also consider therapy as part of a strategy aimed at reducing the burden of the disease and lowering the risk of cardiovascular, renal, ophthalmic, and other complications.
Each case is reviewed individually during an online consultation.
To learn more about stem cell treatment for type 1 diabetes, check the link in the comments.
Share this with someone who needs it ↗️
